The prevalence of pulmonary hypertension in patients with obesity hypoventilation syndrome: a prospective observational study

Almeneessier, Aljohara S.; Nashwan, Samar Z.; Alshamiri, Mostafa Q; Pandi-Perumal, Seithikurippu R.; BaHammam, Ahmed S.

doi:10.21037/jtd.2017.03.21

Cited by 35 publications

(22 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…; Almeneessier et al . ; Kaw, ). In addition, we will not discuss details about aminorex fumarate, fenfluramine and dexfenfluramine in this review.…”

Section: Vascular Function In Obesitymentioning

confidence: 99%

Pulmonary vascular dysfunction in metabolic syndrome

Willson

Watanabe

Tsuji‐Hosokawa

2018

The Journal of Physiology

View full text Add to dashboard Cite

Metabolic syndrome is a critically important precursor to the onset of many diseases, such as cardiovascular disease, and cardiovascular disease is the leading cause of death worldwide. The primary risk factors of metabolic syndrome include hyperglycaemia, abdominal obesity, dyslipidaemia, and high blood pressure. It has been well documented that metabolic syndrome alters vascular endothelial and smooth muscle cell functions in the heart, brain, kidney and peripheral vessels. However, there is less information available regarding how metabolic syndrome can affect pulmonary vascular function and ultimately increase an individual's risk of developing various pulmonary vascular diseases, such as pulmonary hypertension. Here, we review in detail how metabolic syndrome affects pulmonary vascular function.

show abstract

“…; Almeneessier et al . ; Kaw, ). In addition, we will not discuss details about aminorex fumarate, fenfluramine and dexfenfluramine in this review.…”

Section: Vascular Function In Obesitymentioning

confidence: 99%

Pulmonary vascular dysfunction in metabolic syndrome

Willson

Watanabe

Tsuji‐Hosokawa

2018

The Journal of Physiology

View full text Add to dashboard Cite

show abstract

“…Obesity‐hypoventilation syndrome occurs with alveolar hypoventilation during sleeping and daytime 1,2 . Obesity was associated with risk of venous thromboembolic disease 3 .…”

Section: Introductionmentioning

confidence: 99%

Pulmonary embolism in obesity‐hypoventilation syndrome

Ekici

İleri

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction Obesity‐hypoventilation syndrome occurs with alveolar hypoventilation during sleeping and daytime. Obesity may be a risk factor for venous thromboembolism. However, the venous thromboembolism in the obesity‐hypoventilation syndrome is not well characterized. Objective This case series aimed to investigate the presence and clinical features of venous thromboembolism in patients with the obesity‐hypoventilation syndrome. Methods Data of eight case reports were collected. Ages ranged from 36 to 73 years. Results All patients had mosaic perfusion and enlarged main pulmonary artery, two had signs of infarction and mostly segmental and subsegmental filling defects. On the basis of this information some conclusions can be drawn carefully. Conclusion Present cases indicate that pulmonary embolism are also very common in patients with obesity‐hypoventilation syndrome, anticoagulant therapy is at least as important as the treatment of the current disease. Clinicians will frequently be faced with patients with obesity‐hypoventilation syndrome suspected of PE.

show abstract

“…6 In addition to left heart failure, coronary heart disease and systemic hypertension, pulmonary hypertension (PH) is an important feature in OHS. [7][8][9] However, robust data on PH in OHS, particularly its prevalence in patients with NPPV, are scarce. [9][10][11][12][13] In a previous work, we determined PH by right heart catheterization (RHC) in a prospective cross-sectional study of clinically stable OHS patients, treated with NPPV for at least 3 months.…”

Section: Introductionmentioning

confidence: 99%

“…14 It has been hypothesised that PH in OHS is predominately linked to pulmonary vascular response to hypercapnia and hypoxia, 15 although pulmonary artery pressure obviously cannot be normalised in all patients despite NPPV therapy. [8][9][10]13,14 Surprisingly, PH has not yet been systematically explored in a larger cohort of patients with OHS with regard to long-term outcome, although Masa and coworkers recently showed that in patients with OHS and concomitant severe OSA, NPPV led to a reduction of systolic pulmonary artery pressure and left ventricle diastolic dysfunction. 13 Based on these considerations and the known impact of PH in other respiratory and/or pulmonary diseases, 16 we hypothesised that PH is a major prognostic factor in OHS and related to subjective outcome measures.…”

Section: Introductionmentioning

confidence: 99%

Long‐term outcome with focus on pulmonary hypertension in Obesity Hypoventilation Syndrome

Budweiser

Tratz

Gfüllner

et al. 2020

Clinical Respiratory J

View full text Add to dashboard Cite

Introduction: Pulmonary Hypertension (PH) is a frequent comorbidity in Obesity Hypoventilation Syndrome (OHS). Objective: We investigated long-term outcome of OHS with a particular emphasis on PH. Methods: In a prospective design, 64 patients with OHS and established noninvasive positive pressure ventilation (NPPV), were assessed by serum biomarkers, right heart catheterization, blood gases analysis, lung function, Epworth-Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), World Health Organizationfunctional class (WHO-FC) and health-related quality of life (HRQL) via the Severe Respiratory Insufficiency (SRI) questionnaire. After a planned follow-up of 5 years patients were reassessed regarding vital status, WHO-FC, ESS, SRI, PSQI, body mass index (BMI) and NPPV use. Prognostic markers were explored using univariate and multivariate Cox regression analyses. Results: At the 5-year follow-up, BMI tended to decrease (P = 0.05), while WHO-FC, ESS and PSQI remained unchanged. HRQL deteriorated in terms of SRI summary score and most subdomains (P < .05 each). NPPV adherence still was high (89%), while daily NPPV use increased from 6.7 (5.1; 8.0) h/d to 8.2 (7.4; 9.0) h/d (P < .05). After a 5-year follow-up, mortality was 25.8%. In univariate regression analyses only age > 69.5 years (HR = 4.145, 95%-CI = 1.180-14.565, P = 0.016), NT-proBNP > 1256 pg/mL (HR = 5.162, 95%-CI = 1.136-23.467, P = 0.018), diffusion capacity for carbon monoxide (DLCO, %pred) (HR = 0.341, 95%-CI = 0.114-1.019, P = 0.043) and higher oxygen use during daytime (HR = 5.236, 95%-CI = 1.489-18.406, P = 0.004) predicted mortality. No independent factor predicting mortality was detected in multivariate analysis. Conclusion: Despite a high long-term NPPV use HRQL worsened. Age, oxygen use at baseline, DLCO (%pred) and NT-proBNP, as a surrogate parameter for PH, were related to long-term survival.

show abstract

The prevalence of pulmonary hypertension in patients with obesity hypoventilation syndrome: a prospective observational study

Abstract: PH is very common among patients with OHS who have been referred to sleep disorders clinics. PH should be considered in the regular clinical assessment of all patients with OHS.

Cited by 35 publications

References 35 publications

Pulmonary vascular dysfunction in metabolic syndrome

Pulmonary vascular dysfunction in metabolic syndrome

Pulmonary embolism in obesity‐hypoventilation syndrome

Long‐term outcome with focus on pulmonary hypertension in Obesity Hypoventilation Syndrome

Contact Info

Product

Resources

About